Amalgamated Bank reduced its position in shares of The Medicines Company (NASDAQ:MDCO) by 0.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,946 shares of the company’s stock after selling 11 shares during the period. Amalgamated Bank’s holdings in The Medicines were worth $437,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in MDCO. PNC Financial Services Group Inc. raised its stake in shares of The Medicines by 341.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,109 shares of the company’s stock worth $104,000 after buying an additional 1,631 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of The Medicines by 5.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,496 shares of the company’s stock worth $122,000 after buying an additional 120 shares during the last quarter. Neuburgh Advisers LLC raised its stake in shares of The Medicines by 12.4% in the first quarter. Neuburgh Advisers LLC now owns 2,596 shares of the company’s stock worth $127,000 after buying an additional 286 shares during the last quarter. Tyers Asset Management LLC raised its stake in shares of The Medicines by 12.4% in the first quarter. Tyers Asset Management LLC now owns 3,304 shares of the company’s stock worth $162,000 after buying an additional 364 shares during the last quarter. Finally, US Bancorp DE raised its stake in shares of The Medicines by 1.7% in the first quarter. US Bancorp DE now owns 3,413 shares of the company’s stock valued at $167,000 after buying an additional 58 shares in the last quarter.
Shares of The Medicines Company (NASDAQ MDCO) traded up 0.83% during trading on Friday, hitting $36.43. The stock had a trading volume of 784,165 shares. The company’s 50 day moving average price is $38.29 and its 200 day moving average price is $44.64. The company’s market capitalization is $2.59 billion. The Medicines Company has a 52 week low of $30.80 and a 52 week high of $55.95.
WARNING: This story was originally posted by BBNS and is the property of of BBNS. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://baseballnewssource.com/markets/amalgamated-bank-sells-11-shares-of-the-medicines-company-mdco-updated-updated-updated/1179676.html.
A number of research analysts recently weighed in on MDCO shares. Citigroup Inc. raised their price objective on The Medicines from $43.00 to $45.00 and gave the company a “neutral” rating in a research note on Wednesday, July 26th. Jefferies Group LLC restated a “buy” rating and set a $62.00 price objective on shares of The Medicines in a research report on Wednesday, April 12th. CIBC set a $50.00 price objective on The Medicines in a research report on Tuesday, May 23rd. ValuEngine upgraded The Medicines from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, Oppenheimer Holdings, Inc. began coverage on The Medicines in a research note on Monday, May 22nd. They issued a “market perform” rating and a $50.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $53.55.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with our FREE daily email newsletter.